Xtant Medical Holdings (XTNT) AI Stock Analysis

• Market Cap: $66.74M
• Dividend Yield: N/A
• Average Volume (3M): 77.02K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.04
• Revenue Growth: 28.44%
• EPS Growth: -61600.00%
• Country: US
• Employees: 217
• Sector: Healthcare
• Sector Strength: 70
• Industry: Medical - Devices
• EPS (TTM): -0.12
• Shares Outstanding: 139,067,920
• 10 Day Avg. Volume: 146,691
• 30 Day Avg. Volume: 77,020
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.36
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: 1.33
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $2.00
• Price Target Upside: 292.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Xtant Medical Holdings' overall stock score reflects significant financial challenges, with persistent losses and liquidity issues being major concerns. While there is potential for growth through strategic shifts and investor alignment, weak valuation and mixed technical indicators suggest considerable risks. Successful execution of strategic initiatives and improvements in financial performance are critical for enhancing stock performance.

Xtant Medical Holdings Business Overview & Revenue Model

Company Description

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; OsteoFactor, which contains various proteins and peptides that support bone formation and remodeling; OsteoWrap; and OsteoVive Plus, a growth factor enriched cellular bone matrix. The company also provides 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. Further, the company offers Certex spinal fixation, Spider cervical plating, Axle interspinous fusion, Silex Sacroiliac joint fusion, Xpress minimally invasive pedicle screw, and Fortex Pedicle screw systems. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous fusion system, Irix-C cervical integrated fusion system, and Irix-A Lumbar integrated fusion system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.

How the Company Makes Money

Xtant Medical Holdings makes money primarily through the sale of its medical devices and biologic products to healthcare providers, including hospitals and surgery centers. The company generates revenue by marketing and distributing its comprehensive portfolio of spinal implants and biologics used in orthopedic surgeries. Revenue streams are driven by the demand for innovative surgical solutions that enhance surgical outcomes and patient recovery. Furthermore, Xtant Medical may engage in strategic partnerships with healthcare institutions and distributors to expand its market reach and enhance its distribution network.

Xtant Medical Holdings Financial Statement Overview

Summary

Xtant Medical Holdings shows a challenging financial landscape with consistent revenue growth but persistent losses in profitability and cash flow. While the balance sheet reflects improved leverage, profitability and liquidity remain significant concerns. Improvements in cost management are crucial for future financial health.

Income Statement

The company exhibits a mixed financial performance with a notable growth in revenue from 2023 to 2024 by approximately 28.5%. However, profitability metrics are concerning with consistent negative EBIT and net income over the years, indicating operational inefficiencies. The gross profit margin remains relatively stable but is overshadowed by high operating expenses leading to negative margins. This suggests a need for cost management improvements.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, which improved from 0.46 in 2023 to 0.30 in 2024 due to reduced total debt and increased equity. The equity ratio is healthy at around 45.8%, indicating a solid capital structure. However, the negative net income has impacted the return on equity, which remains negative. Overall, there is a moderate level of financial stability but room for strengthening equity returns.

Cash Flow

The cash flow statement highlights significant challenges with negative operating and free cash flows indicating cash consumption in operations. The free cash flow declined by about 46% from 2023 to 2024, highlighting growing cash constraints. The operating cash flow to net income ratio is negative, reflecting inefficiencies in cash generation relative to earnings. This points to potential liquidity risks if these trends continue.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
117.27M	91.30M	57.97M	55.26M	53.34M
	Gross Profit
68.22M	55.47M	32.14M	32.49M	34.39M
	EBIT
-12.07M	-10.16M	-6.75M	-3.85M	-751.00K
	EBITDA
-12.07M	5.07M	-5.43M	-2.51M	1.33M
	Net Income Common Stockholders
-16.45M	660.00K	-8.48M	-5.84M	-7.02M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
6.20M	5.71M	20.30M	18.24M	2.34M
	Total Assets
93.84M	92.61M	60.23M	54.69M	41.47M
	Total Debt
12.94M	23.56M	17.07M	16.84M	18.54M
	Net Debt
6.74M	17.84M	-3.23M	-1.40M	16.20M
	Total Liabilities
50.87M	41.26M	26.06M	23.81M	26.95M
	Stockholders Equity
42.96M	51.35M	34.17M	30.88M	14.51M
Cash Flow		Free Cash Flow
-16.01M	-10.97M	-7.11M	-1.68M	-2.28M
	Operating Cash Flow
-11.90M	-9.52M	-5.34M	439.00K	-731.00K
	Investing Cash Flow
-3.73M	-24.78M	-1.56M	-1.89M	-1.30M
	Financing Cash Flow
16.07M	19.69M	9.02M	17.50M	-861.00K

Xtant Medical Holdings Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.51
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XTNT, the sentiment is Positive. The current price of 0.51 is above the 20-day moving average (MA) of 0.45, above the 50-day MA of 0.48, and below the 200-day MA of 0.54, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 54.49 is Neutral, neither overbought nor oversold. The STOCH value of 75.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XTNT.

Xtant Medical Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XGN	61 Neutral	$76.25M	―	-93.78%	―	5.89%	38.12%
Sector *	52 Neutral	$5.38B	3.59	-41.63%	2.87%	17.72%	1.87%
XTNT	51 Neutral	$66.74M	―	-34.88%	―	28.44%	-61600.00%
CRBP	43 Neutral	$91.74M	―	-59.34%	―	―	64.71%
CBUS	36 Underperform	$74.31M	―	-130.38%	―	134.56%	61.91%
ACET	27 Underperform	$51.26M	―	-65.65%	―	―	59.75%

Xtant Medical Holdings Corporate Events

Xtant Medical Ends Investor Agreement After Share Sale

On April 15, 2025, Xtant Medical Holdings terminated its Investor Rights Agreement with ROS Acquisition and ORO II following a secondary private sale of 73.1 million shares by OrbiMed to Nantahala Capital Management and other investors. This transaction provides Xtant with greater strategic flexibility and aligns it with long-term healthcare-focused investors. Xtant plans to prioritize profitability and self-sustainability by shifting towards higher-margin orthobiologics and leveraging its Montana manufacturing facility. The company anticipates revenue growth of 18% to 19% for the first quarter of 2025, driven by orthobiologics and licensing revenue.

Spark’s Take on XTNT Stock

According to Spark, TipRanks’ AI Analyst, XTNT is a Neutral.

Xtant Medical Holdings’ overall stock score is primarily impacted by its ongoing financial struggles, including persistent losses and liquidity issues. While there is some optimism from projected revenue growth and cost-cutting strategies, the negative trend in technical analysis and weak valuation metrics underscore significant risks. Improvements in financial performance and successful execution of strategic initiatives will be crucial for future stock performance.

To see Spark’s full report on XTNT stock, click here.